Avalo Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is AVTX moving today?
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for AVTX.
AVTX insider activity
Avalo Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for AVTX.
AVTX contract awards, year to date.
Public federal awards linked to this ticker.
AVTX lobbying filings, year to date.
Registered lobbying filings matched to Avalo Therapeutics, Inc. Common Stock.